<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04173104</url>
  </required_header>
  <id_info>
    <org_study_id>19-311</org_study_id>
    <nct_id>NCT04173104</nct_id>
  </id_info>
  <brief_title>PET and MRI Imaging of Brain Tumors Using [18F]PARPi</brief_title>
  <official_title>Pilot Study of [18F]PARPi PET/MR Imaging in Patients With New and/or Suspected Recurrent Brain Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to collect data about how 18FPARPi can be used together with PET/positron
      emission tomography and MRI/magnetic resonance imaging scans to take pictures of brain cancer
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>SUVmax measurements</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>[18F]PARPi updtake in lesions will be quantified by standard SUVmax measurements from PET/MR scans</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Brain Tumor</condition>
  <condition>Brain Cancer</condition>
  <arm_group>
    <arm_group_label>Participants with Brain Cancer</arm_group_label>
    <description>Participants with new or suspected recurrent brain tumors</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PET/MR with [18F]PARPi</intervention_name>
    <description>One PET/MR study (with up to 3 scan times) with [18F]PARPi</description>
    <arm_group_label>Participants with Brain Cancer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]PARPi</intervention_name>
    <description>Injection of &lt;100ug of [18F]PARPi prior to 1 PET/MR</description>
    <arm_group_label>Participants with Brain Cancer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Potential study participants will be identified by a member of the patient's treatment team
        at MSK. Women and men of all races and ethnic groups will be considered for study
        participation. Candidates must conform to all inclusion and exclusion criteria to be
        accepted into the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with new or suspected recurrent brain tumors (including suspected recurrent
             brain tumors showing growth from any preceding scan)

          -  Age &gt;/= 18 years

          -  Minimum at least one brain lesion size &gt;/= 1.5cm diameter

          -  Scheduled to undergo treatment at MSK

          -  Willingness to sign informed consent

          -  Able to receive intravenous gadolinium contrast per MSK Department of Radiology
             guidelines

        Exclusion Criteria:

          -  Any contraindication to 3T MRI (PET/MR scanner is 4.0 Tesla)

          -  Pregnancy or breast-feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Young, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert Young, MD</last_name>
    <phone>1212-639-8196</phone>
    <email>youngr@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mark Dunphy, DO</last_name>
    <phone>1212-639-8131</phone>
    <email>dunphym@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Young, MD</last_name>
      <phone>212-639-8196</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 19, 2019</study_first_submitted>
  <study_first_submitted_qc>November 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2019</study_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brain cancer</keyword>
  <keyword>18FPARPi</keyword>
  <keyword>PET scan</keyword>
  <keyword>MRI</keyword>
  <keyword>Memorial Sloan Kettering Cancer Center</keyword>
  <keyword>19-311</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

